The American College of Cardiology’s 73rd Annual Scientific Session & Expo (ACC24) took place over the weekend in Atlanta, spotlighting the latest and most impactful innovations in the field of cardiovascular care.
Tag Archive for: Ionis Pharmaceuticals
Ionis Pharmaceuticals said on Wednesday its experimental drug to treat a type of fatty liver disease met the main goal of reducing inflammation of the critical organ in a mid-stage trial.
The drug candidate, olezarsen, showed statistically significant reduction in levels of triglyceride compared to placebo, as well as showed a 100% reduction in inflammation of the pancreas.
With a potential $2.9 billion on the line, Ionis Pharmaceuticals and AstraZeneca announced new results from the Phase III study of eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The results will be presented Monday at the American Academy of Neurology (AAN) 2023 Annual Meeting in Boston.
California-based Vera Therapeutics unveiled results Tuesday from the Phase IIb ORIGIN trial showing its immunoglobulin A nephropathy (IgAN) candidate atacicept met the primary endpoint of reduced proteinuria.
Ionis Pharmaceuticals Inc. announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for review of tofersen, an investigational medicine for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-ALS is a progressive and uniformly fatal disease that affects fewer than 1,000 people across Europe.
Ionis Pharmaceuticals inked a collaboration deal with Metagenomi with the goal of adding DNA editing to its RNA-targeted technologies focused on up to four genetic targets.
Preliminary findings from the NEURO-TTRansform trial show Ionis Pharmaceuticals’ and AstraZeneca’s antisense candidate, eplontersen, is potentially a safe and effective treatment for patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
An interim analysis of AstraZeneca and partner Ionis Pharmaceuticals’ eplontersen showed the experimental drug met the main goals in a late-stage trial in patients with a rare, fatal disease, the Anglo-Swedish drugmaker said on Tuesday.
Biogen and Ionis Pharmaceuticals have announced results from the Phase III VALOR trial and an open-label extension trial of the amyotrophic lateral sclerosis (ALS) hopeful tofersen. This data suggests that earlier initiation of the drug compared to delayed initiation decreased declines in clinical function, respiratory function, muscle strength and quality of life.
